Key result
Breakapart probe FISH identified SYT disruption in 96% of known synovial sarcoma samples, compared to 81% using commercial FISH probes.
Why the study?
Does a breakapart probe FISH scoring method accurately detect SYT gene disruption in synovial sarcoma tissue microarrays compared to commercial probes?
Observational (n=57)
Blinded
Does a breakapart probe FISH scoring method accurately detect SYT gene disruption in synovial sarcoma tissue microarrays compared to commercial probes?
Absolute Event Rate: 96% vs 81%
Breakapart FISH probes provide a relatively quick and accurate method for detecting synovial sarcoma translocations in archival tissue microarrays.
May improve SYT detection in archival synovial sarcoma samples; leaves open need for prospective clinical validation.
Synovial sarcomas (SSs) account for 5% of soft tissue tumors and carry a balanced translocation t(X;18)(p11.2;q11.2), detectable in over 90% of cases. This translocation brings together portions of two genes: SYT and SSX. Detecting interruption of the SYT gene on chromosome 18 would be useful as a diagnostic tool. We describe a scoring method to detect disruption of SYT with breakapart probe fluorescence in situ hybridization (FISH) and the application of this method for identification of SS within a sarcoma tissue microarray. After optimization, SYT disruption was identified in 22 of 23 (96%) of known SS tumor samples but was not in 23 of 23 (100%) of non-SS sarcoma samples. Ten of 11 (91%) blinded test SS tumor samples were also correctly identified. For comparison, commercially available FISH and chromogenic in situ hybridization (CISH) probes were tested. The commercial FISH probes identified SYT disruption in 81% of the SS tumor samples but in none of the non-SS samples. The CISH probes produced signals too weak to interpret. The use of breakapart FISH probes is a relatively quick procedure for detection of synovial sarcoma translocations and can be applied to archival specimens in tissue microarrays.
No takes yet. Share an insight, caveat, or question.
Terry et al. (2005) conducted an observational in Synovial sarcoma (n=57). Breakapart probe fluorescence in situ hybridization (FISH) vs. Commercial FISH and chromogenic in situ hybridization (CISH) probes was evaluated on Identification of SYT disruption in known synovial sarcoma tumor samples. Breakapart probe FISH identified SYT disruption in 96% of known synovial sarcoma samples, compared to 81% using commercial FISH probes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: